{"protocolSection":{"identificationModule":{"nctId":"NCT05281549","orgStudyIdInfo":{"id":"PR-SMTJ-2019001F"},"organization":{"fullName":"Beijing Tiantan Hospital","class":"OTHER"},"briefTitle":"Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）","officialTitle":"Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Controlled Phase II Trial"},"statusModule":{"statusVerifiedDate":"2022-03","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-05-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-01-28","type":"ACTUAL"},"completionDateStruct":{"date":"2022-05-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-03-07","studyFirstSubmitQcDate":"2022-03-07","studyFirstPostDateStruct":{"date":"2022-03-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-03-16","lastUpdatePostDateStruct":{"date":"2022-03-31","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Yongjun Wang","investigatorTitle":"President of Beijing Tiantan Hospital, Capital Medical University, Director of Neurology Center","investigatorAffiliation":"Beijing Tiantan Hospital"},"leadSponsor":{"name":"Beijing Tiantan Hospital","class":"OTHER"},"collaborators":[{"name":"Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd","class":"UNKNOWN"},{"name":"The Place Pharmaceutical(Jiangsu) Co., Ltd","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The trial is prospective, block randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be randomized 1:1:1 to 0.25mg/kg or 0.40mg/kg intravenous tenecteplase or 0.9 mg/kg alteplase before all participants undergo endovascular thrombectomy.","detailedDescription":"The study will be a multi-center, prospective, randomized, open- label, blinded endpoint (PROBE), controlled phase 2 trial (3 arm with 1:1:1 randomization) in ischemic stroke patients. Imagine is performed with CT or MRI acutely with imaging follow-up at 24-30 hours. The sample size is 225."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["TNK-tPA","rt-PA","Acute stroke","phase II trial"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":225,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Alteplase","type":"ACTIVE_COMPARATOR","description":"Patients will receive intravenous Alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.","interventionNames":["Drug: Alteplase"]},{"label":"Tenecteplase 0.25mg/kg","type":"EXPERIMENTAL","description":"Patients will receive intravenous Tenecteplase, 0.25mg/kg, maximum 25mg, administered as a bolus over 5\\~10 seconds","interventionNames":["Drug: Tenecteplase"]},{"label":"Tenecteplase 0.4mg/kg","type":"EXPERIMENTAL","description":"Patients will receive intravenous Tenecteplase, 0.4mg/kg, maximum 40mg, administered as a bolus over 5\\~10 seconds","interventionNames":["Drug: Tenecteplase"]}],"interventions":[{"type":"DRUG","name":"Alteplase","description":"Alteplase 0.9mg/kg are being used.","armGroupLabels":["Alteplase"],"otherNames":["rt-PA"]},{"type":"DRUG","name":"Tenecteplase","description":"Tenecteplase 0.25mg/kg are being used.","armGroupLabels":["Tenecteplase 0.25mg/kg"],"otherNames":["TNK-tPA"]},{"type":"DRUG","name":"Tenecteplase","description":"Tenecteplase 0.4mg/kg are being used.","armGroupLabels":["Tenecteplase 0.4mg/kg"],"otherNames":["TNK-tPA"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Modified Rankin Scale(mRS)","description":"Proportion of subjects with mRS scores of (0-1) at 90±7 days.(Comments:The minimum and maximum values are from 0 to 6,and higher scores mean a worse outcome.)","timeFrame":"90±7 days"}],"secondaryOutcomes":[{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"NIHSS score at 24±2 hours.(Comments:The minimum and maximum values are from 0 to 40, and higher scores mean a worse outcome.)","timeFrame":"24±2 hours"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"Proportion of subjects with ≥ 4 point reduction in NIHSS or reaching 0-1 at 7 ± 2 days or before discharge (whichever occurs first).(Comments:The minimum and maximum values are from 0 to 40, and higher scores mean a worse outcome.)","timeFrame":"7±2days or discharge"},{"measure":"Modified Rankin Scale(mRS)","description":"Proportion of subjects with mRS scores of (0-2) at 90±7 days.(Comments:The minimum and maximum values are from 0 to 6,and higher scores mean a worse outcome.)","timeFrame":"90±7 days"},{"measure":"Modified Rankin Scale(mRS)","description":"mRS scores at 90±7 days.(Comments:The minimum and maximum values are from 0 to 6,and higher scores mean a worse outcome.)","timeFrame":"90±7 days"},{"measure":"The new vascular events","description":"Incidence of the new vascular events, ischemic stroke, hemorrhagic stroke, myocardial infarction and cardio-cerebral revascularization at 90±7 days. (including: carotid endarterectomy, intracranial and extracranial artery interventional therapy, intracranial and extracranial artery bypass surgery, coronary interventional or bypass therapy)","timeFrame":"90±7 days"},{"measure":"Deaths","description":"Vascular mortality at 90±7 days (mainly due to stroke, myocardial infarction or pulmonary embolism)","timeFrame":"90±7 days"},{"measure":"EQ-5D","description":"EQ-5D scores at 90±7 days.(Comments:The minimum and maximum values are from 0 to 100,and higher scores mean a better outcome.)","timeFrame":"90±7 days"}],"otherOutcomes":[{"measure":"Symptomatic intracranial hemorrhage(sICH)","description":"Incidence of symptomatic intracranial hemorrhage (sICH) within 24\\~30 hours.( According to ECASSII)","timeFrame":"24~30 hours post treatment"},{"measure":"Parenchymal hematoma type 2(PH2) intracranial hemorrhage","description":"Incidence of intracranial hemorrhage (PH2) within 24\\~30 hours.","timeFrame":"24~30 hours post treatment"},{"measure":"Any intracranial hemorrhage","description":"Incidence of any intracranial hemorrhage within 24\\~30 hours.","timeFrame":"24~30 hours post treatment"},{"measure":"Systematic bleeding","description":"Incidence of Systematic bleeding within 30 hours. ( defined by PLATO)","timeFrame":"30 hours"},{"measure":"Deaths","description":"Mortality due to any cause at 90±7days.","timeFrame":"90±7 days"},{"measure":"AEs/SAEs","description":"Incidence of adverse events(AEs) / severe adverse events(SAEs) at 90±7 days.","timeFrame":"90±7 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 years old;\n* The clinical diagnosis was Acute ischemic stroke The time from onset to treatment was \\< 4.5h; The time at which symptoms begin is defined as \"the time at which they finally appear normal\";\n* mRS before onset was ≤1 points;\n* Baseline NIHSS (at the time of randomization) should be \\> 5 and ≤25 points;\n* Informed consent from the patient or surrogate.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage identified by CT or MRI (CMBs detected by SWI is not counted);\n* Massive anterior cerebral infarction identified by CT or MRI (ASPECT \\< 6 or lesions larger than one third of the territory of the middle cerebral artery or with a volume larger than 70mL)\n* A history of severe CNS damage (such as aneurysm or arteriovenous malformation, craniocerebral trauma, intracranial or spinal cord surgery)\n* Onset with seizures, and the paralysis was suspected to be related to Todd paralysis.\n* Administration of heparin within 48 hours preceding the onset of stroke with a baseline APTT exceeding the upper limit of the normal range.\n* Oral anticoagulant (such as warfarin) treatment with baseline INR\\>1.7 or PT\\>15 s;\n* Administration of thrombin inhibitors or factor Xa inhibitors within 48 hours preceding the onset of stroke with abnormal coagulation parameters or platelet count;\n* BP couldn't be controlled with aggressive treatment. Uncontrolled hypertension was defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg, measured for three times every 10 minutes.\n* Platelet count of less than 100×109/ L;\n* Blood glucose \\<50 mg/dl (\\<2.8 mmol/L) or \\>400 mg/dl (22.22 mmol/L);\n* History of intracranial hemorrhage or active hemorrhagic disease. (Such as gastrointestinal, urinary tract or retinal bleeding)\n* Tumors with an increased risk of bleeding.\n* Prolonged or traumatic cardiopulmonary resuscitation (\\>2 min), delivery within the last 10 days or recent puncture of non-compression vessels such as subclavian vein or jugular vein\n* Acute pancreatitis or severe liver disease, including liver failure, cirrhosis, portal hypertension, esophageal varicose veins, and active hepatitis;\n* Aortic arch dissection;\n* Major surgery or severe trauma in the past 2 weeks;\n* Subjects had serious, fatal, or disabling disease with an expected survival of less than 3 months;\n* Unable to complete neurological assessment and follow-up visits because of dementia or mental illness;\n* Pregnant women, lactating women, or have positive pregnancy test;\n* Allergy to tenecteplase or alteplase or their components;\n* Participation in other clinical trials within 3 months prior to screening;\n* Unsuitable to involve in this study or would result in increased risk, as judged by the investigators.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Shuya Li","affiliation":"IRB of Beijing Tiantan Hospital,Capital Medical University","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Beijing Tiantan Hospital, Capital Medical University Beijing","city":"Beijing","state":"Beijing","zip":"100000","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Quanzhou First Hospital","city":"Quanzhou","state":"Fujian","zip":"362000","country":"China","geoPoint":{"lat":24.91389,"lon":118.58583}},{"facility":"Yue Bei People'S Hospital","city":"Shaoguan","state":"Guangdong","zip":"512000","country":"China","geoPoint":{"lat":24.8,"lon":113.58333}},{"facility":"Hengshui people's Hospital (Harrison International Peace Hospital)","city":"Hengshui","state":"Hebei","zip":"053000","country":"China","geoPoint":{"lat":37.73222,"lon":115.70111}},{"facility":"Tangshan Gongren Hospital","city":"Tangshan","state":"Hebei","zip":"063000","country":"China","geoPoint":{"lat":39.63333,"lon":118.18333}},{"facility":"Daqing Oilfield General Hospital","city":"Daqing","state":"Heilongjiang","zip":"163000","country":"China","geoPoint":{"lat":46.58333,"lon":125.0}},{"facility":"Baogang Hospital of Inner Monglia","city":"Baotou","state":"Inner Monglia","zip":"014010","country":"China","geoPoint":{"lat":40.65222,"lon":109.82222}},{"facility":"Inner Mongolia Baotou Hospital","city":"Baotou","state":"Inner Mongolia","zip":"014040","country":"China","geoPoint":{"lat":40.65222,"lon":109.82222}},{"facility":"Huai'an Second People's Hospital","city":"Huai'an","state":"Jiangsu","zip":"121000","country":"China","geoPoint":{"lat":33.50389,"lon":119.14417}},{"facility":"The Affiliated Hospital of Xuzhou Meidcal University","city":"Xuzhou","state":"Jiangsu","zip":"221006","country":"China","geoPoint":{"lat":34.18045,"lon":117.15707}},{"facility":"The First Hospital of Jilin University","city":"Changchun","state":"Jilin","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Mei He Kou Central Hospital","city":"Meihekou","state":"Jilin","zip":"135000","country":"China","geoPoint":{"lat":42.52722,"lon":125.67528}},{"facility":"Jilin Guowen Hospital","city":"Siping","state":"Jilin","zip":"136100","country":"China","geoPoint":{"lat":43.16143,"lon":124.37785}},{"facility":"The First People's Hospital of Yinchuan","city":"Yinchuan","state":"Ningxia","zip":"750001","country":"China","geoPoint":{"lat":38.46806,"lon":106.27306}},{"facility":"General Hospital of Ningxia Medical University","city":"Yinchuan","state":"Ningxia","zip":"750004","country":"China","geoPoint":{"lat":38.46806,"lon":106.27306}},{"facility":"Shandong Provincial Third Hospital","city":"Jinan","state":"Shandong","zip":"250000","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Liaocheng People'S Hospital","city":"Liaocheng","state":"Shandong","zip":"252006","country":"China","geoPoint":{"lat":36.45596,"lon":115.97766}},{"facility":"Linyi City People Hospital","city":"Linyi","state":"Shandong","zip":"276000","country":"China","geoPoint":{"lat":35.06306,"lon":118.34278}},{"facility":"Qingdao Central Hospital","city":"Qingdao","state":"Shandong","zip":"266000","country":"China","geoPoint":{"lat":36.06488,"lon":120.38042}},{"facility":"Yantai Yuhangding Hospital","city":"Yantai","state":"Shandong","zip":"264000","country":"China","geoPoint":{"lat":37.47649,"lon":121.44081}},{"facility":"Shanghai Pudong Hospital","city":"Shanghai","state":"Shanghai","zip":"201200","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Changzhi People'S Hospital","city":"Changzhi","state":"Shanxi","zip":"046000","country":"China","geoPoint":{"lat":35.20889,"lon":111.73861}},{"facility":"The First People's Hospital of Jinzhong","city":"Jinzhong","state":"Shanxi","zip":"030602","country":"China"},{"facility":"First Hospital of Shanxi Medical University","city":"Taiyuan","state":"Shanxi","zip":"030001","country":"China","geoPoint":{"lat":37.86944,"lon":112.56028}},{"facility":"Dazhu County People's Hospital","city":"Dazhou","state":"Sichuan","zip":"635199","country":"China","geoPoint":{"lat":31.21592,"lon":107.50092}},{"facility":"Zigong First People'S Hospital","city":"Zigong","state":"Sichuan","zip":"643000","country":"China","geoPoint":{"lat":29.34162,"lon":104.77689}},{"facility":"Zhejiang Provincial People'S Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310000","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Taizhou Hospital of Zhejiang Province","city":"Taizhou","state":"Zhejiang","zip":"318000","country":"China","geoPoint":{"lat":32.49069,"lon":119.90812}}]},"referencesModule":{"references":[{"pmid":"20185783","type":"RESULT","citation":"Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, Levine SR, Johnston KC, Buchsbaum R, Levy G, Levin B; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010 Apr;41(4):707-11. doi: 10.1161/STROKEAHA.109.572040. Epub 2010 Feb 25."},{"type":"RESULT","citation":"Guidelines Editing Group of Chinese Stroke Society, Guidelines for the Diagnosis and Treatment of High-risk Non-Disabling Ischemic Cerebrovascular Events, Chinese Journal of Stroke, June 2016, 11 (6), p481-491."},{"type":"RESULT","citation":"Chinese Journal of Circulation, China Cardiovascular Disease Report 2015."},{"pmid":"9186381","type":"RESULT","citation":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997 Jun 7;349(9066):1641-9."},{"type":"RESULT","citation":"Hao Zilong, Liu Ming, Li Wei, et al. Stroke registration method and basic characteristics and functional outcomes of 3123 patients in Chengdu [J]. Chinese Journal of Neurology, 2011,12 (44) : 826-831."},{"pmid":"23418571","type":"RESULT","citation":"Wang Z, Li J, Wang C, Yao X, Zhao X, Wang Y, Li H, Liu G, Wang A, Wang Y. Gender differences in 1-year clinical characteristics and outcomes after stroke: results from the China National Stroke Registry. PLoS One. 2013;8(2):e56459. doi: 10.1371/journal.pone.0056459. Epub 2013 Feb 13."},{"pmid":"20651267","type":"RESULT","citation":"Wei JW, Heeley EL, Wang JG, Huang Y, Wong LK, Li Z, Heritier S, Arima H, Anderson CS; ChinaQUEST Investigators. Comparison of recovery patterns and prognostic indicators for ischemic and hemorrhagic stroke in China: the ChinaQUEST (QUality Evaluation of Stroke Care and Treatment) Registry study. Stroke. 2010 Sep;41(9):1877-83. doi: 10.1161/STROKEAHA.110.586909. Epub 2010 Jul 22."},{"pmid":"16574919","type":"RESULT","citation":"Bandera E, Botteri M, Minelli C, Sutton A, Abrams KR, Latronico N. Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. Stroke. 2006 May;37(5):1334-9. doi: 10.1161/01.STR.0000217418.29609.22. Epub 2006 Mar 30."},{"pmid":"19233036","type":"RESULT","citation":"Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol. 2009 Mar;8(3):261-9. doi: 10.1016/S1474-4422(09)70041-9."},{"pmid":"22435369","type":"RESULT","citation":"Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O'Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012 Mar 22;366(12):1099-107. doi: 10.1056/NEJMoa1109842."},{"pmid":"25726502","type":"RESULT","citation":"Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, Ford I, Muir KW. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26."},{"pmid":"28780236","type":"RESULT","citation":"Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Ronning OM, Thommessen B, Amthor KF, Ihle-Hansen H, Kurz M, Tobro H, Kaur K, Stankiewicz M, Carlsson M, Morsund A, Idicula T, Aamodt AH, Lund C, Naess H, Waje-Andreassen U, Thomassen L. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2."},{"pmid":"29694815","type":"RESULT","citation":"Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, Yan B, Bush SJ, Dewey HM, Thijs V, Scroop R, Simpson M, Brooks M, Asadi H, Wu TY, Shah DG, Wijeratne T, Ang T, Miteff F, Levi CR, Rodrigues E, Zhao H, Salvaris P, Garcia-Esperon C, Bailey P, Rice H, de Villiers L, Brown H, Redmond K, Leggett D, Fink JN, Collecutt W, Wong AA, Muller C, Coulthard A, Mitchell K, Clouston J, Mahady K, Field D, Ma H, Phan TG, Chong W, Chandra RV, Slater LA, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Bladin CF, Sharma G, Desmond PM, Parsons MW, Donnan GA, Davis SM; EXTEND-IA TNK Investigators. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018 Apr 26;378(17):1573-1582. doi: 10.1056/NEJMoa1716405."},{"type":"RESULT","citation":"Standards and procedures for rapid reporting of safety data during drug clinical trials"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"},{"id":"D000077785","term":"Tenecteplase"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Morcellation","relevance":"HIGH"},{"id":"M1911","name":"Tenecteplase","asFound":"Early Intervention","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}